Trials / Completed
CompletedNCT04049734
Oral Losartan in Prevention of Post-ERCP Paancreatitis
Evaluation of Oral Losartan in the Prevention of Post-ERCP Pancreatitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50 patients underwent ERCP without receiving oral losartan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oral losatan | 50 mg of oral losartan one hour before the ERCP once |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2017-01-01
- Completion
- 2017-03-01
- First posted
- 2019-08-08
- Last updated
- 2019-08-09
Source: ClinicalTrials.gov record NCT04049734. Inclusion in this directory is not an endorsement.